Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 100


Targeting of renal cell carcinoma with iodine-131-labeled chimeric monoclonal antibody G250.

Steffens MG, Boerman OC, Oosterwijk-Wakka JC, Oosterhof GO, Witjes JA, Koenders EB, Oyen WJ, Buijs WC, Debruyne FM, Corstens FH, Oosterwijk E.

J Clin Oncol. 1997 Apr;15(4):1529-37.


Phase I radioimmunotherapy of metastatic renal cell carcinoma with 131I-labeled chimeric monoclonal antibody G250.

Steffens MG, Boerman OC, de Mulder PH, Oyen WJ, Buijs WC, Witjes JA, van den Broek WJ, Oosterwijk-Wakka JC, Debruyne FM, Corstens FH, Oosterwijk E.

Clin Cancer Res. 1999 Oct;5(10 Suppl):3268s-3274s.


Targeting of metastatic renal cell carcinoma with the chimeric monoclonal antibody G250 labeled with (131)I or (111)In: an intrapatient comparison.

Brouwers AH, Buijs WC, Oosterwijk E, Boerman OC, Mala C, De Mulder PH, Corstens FH, Mulders PF, Oyen WJ.

Clin Cancer Res. 2003 Sep 1;9(10 Pt 2):3953S-60S.


A phase II trial of chimeric monoclonal antibody G250 for advanced renal cell carcinoma patients.

Bleumer I, Knuth A, Oosterwijk E, Hofmann R, Varga Z, Lamers C, Kruit W, Melchior S, Mala C, Ullrich S, De Mulder P, Mulders PF, Beck J.

Br J Cancer. 2004 Mar 8;90(5):985-90.


Anti-renal cell carcinoma chimeric antibody G250: cytokine enhancement of in vitro antibody-dependent cellular cytotoxicity.

Liu Z, Smyth FE, Renner C, Lee FT, Oosterwijk E, Scott AM.

Cancer Immunol Immunother. 2002 May;51(3):171-7. Epub 2002 Mar 1.


Antibody localization in human renal cell carcinoma: a phase I study of monoclonal antibody G250.

Oosterwijk E, Bander NH, Divgi CR, Welt S, Wakka JC, Finn RD, Carswell EA, Larson SM, Warnaar SO, Fleuren GJ, et al.

J Clin Oncol. 1993 Apr;11(4):738-50.


Anti-renal-cell carcinoma chimeric antibody G250 facilitates antibody-dependent cellular cytotoxicity with in vitro and in vivo interleukin-2-activated effectors.

Surfus JE, Hank JA, Oosterwijk E, Welt S, Lindstrom MJ, Albertini MR, Schiller JH, Sondel PM.

J Immunother Emphasis Tumor Immunol. 1996 May;19(3):184-91.


Radiolabeled monoclonal antibody G250 in renal-cell carcinoma.

Oosterwijk E, Debruyne FM.

World J Urol. 1995;13(3):186-90.


Intratumoral distribution of two consecutive injections of chimeric antibody G250 in primary renal cell carcinoma: implications for fractionated dose radioimmunotherapy.

Steffens MG, Boerman OC, Oyen WJ, Kniest PH, Witjes JA, Oosterhof GO, van Leenders GJ, Debruyne FM, Corstens FH, Oosterwijk E.

Cancer Res. 1999 Apr 1;59(7):1615-9.


A phase I multiple dose, dose escalation study of cG250 monoclonal antibody in patients with advanced renal cell carcinoma.

Davis ID, Wiseman GA, Lee FT, Gansen DN, Hopkins W, Papenfuss AT, Liu Z, Moynihan TJ, Croghan GA, Adjei AA, Hoffman EW, Ingle JN, Old LJ, Scott AM.

Cancer Immun. 2007 Aug 17;7:13.


Phase I/II radioimmunotherapy trial with iodine-131-labeled monoclonal antibody G250 in metastatic renal cell carcinoma.

Divgi CR, Bander NH, Scott AM, O'Donoghue JA, Sgouros G, Welt S, Finn RD, Morrissey F, Capitelli P, Williams JM, Deland D, Nakhre A, Oosterwijk E, Gulec S, Graham MC, Larson SM, Old LJ.

Clin Cancer Res. 1998 Nov;4(11):2729-39.


In vivo and in vitro characterizations of three 99mTc-labeled monoclonal antibody G250 preparations.

Steffens MG, Oosterwijk E, Kranenborg MH, Manders JM, Debruyne FM, Corstens FH, Boerman OC.

J Nucl Med. 1999 May;40(5):829-36.


Pharmacokinetic model of iodine-131-G250 antibody in renal cell carcinoma patients.

Loh A, Sgouros G, O'Donoghue JA, Deland D, Puri D, Capitelli P, Humm JL, Larson SM, Old LJ, Divgi CR.

J Nucl Med. 1998 Mar;39(3):484-9.


Pharmacokinetics and tumor targeting of 131I-labeled F(ab')2 fragments of the chimeric monoclonal antibody G250: preclinical and clinical pilot studies.

Brouwers A, Mulders P, Oosterwijk E, Buijs W, Corstens F, Boerman O, Oyen W.

Cancer Biother Radiopharm. 2004 Aug;19(4):466-77.


A prospective open-label single-arm phase II study of chimeric monoclonal antibody cG250 in advanced renal cell carcinoma patients.

Varga Z, de Mulder P, Kruit W, Hegele A, Hofmann R, Lamers C, Warnaar S, Mala C, Ullrich S, Mulders P.

Folia Biol (Praha). 2003;49(2):74-7.


Targeted therapy of renal cell carcinoma: synergistic activity of cG250-TNF and IFNg.

Bauer S, Oosterwijk-Wakka JC, Adrian N, Oosterwijk E, Fischer E, Wüest T, Stenner F, Perani A, Cohen L, Knuth A, Divgi C, Jäger D, Scott AM, Ritter G, Old LJ, Renner C.

Int J Cancer. 2009 Jul 1;125(1):115-23. doi: 10.1002/ijc.24359.


A pilot study of monoclonal antibody cG250 and low dose subcutaneous IL-2 in patients with advanced renal cell carcinoma.

Davis ID, Liu Z, Saunders W, Lee FT, Spirkoska V, Hopkins W, Smyth FE, Chong G, Papenfuss AT, Chappell B, Poon A, Saunder TH, Hoffman EW, Old LJ, Scott AM.

Cancer Immun. 2007 Aug 17;7:14.


Lack of efficacy of two consecutive treatments of radioimmunotherapy with 131I-cG250 in patients with metastasized clear cell renal cell carcinoma.

Brouwers AH, Mulders PF, de Mulder PH, van den Broek WJ, Buijs WC, Mala C, Joosten FB, Oosterwijk E, Boerman OC, Corstens FH, Oyen WJ.

J Clin Oncol. 2005 Sep 20;23(27):6540-8.


Technology evaluation: WX-G250, Wilex/Ludwig Institute for Cancer Research.

Kennett RH.

Curr Opin Mol Ther. 2003 Feb;5(1):70-5.


Generation of chimeric bispecific G250/anti-CD3 monoclonal antibody, a tool to combat renal cell carcinoma.

Luiten RM, Coney LR, Fleuren GJ, Warnaar SO, Litvinov SV.

Br J Cancer. 1996 Sep;74(5):735-44.

Items per page

Supplemental Content

Write to the Help Desk